At a glance
- What the study gets you
- Access to the study treatment being tested
- Type of study
- Interventional (receives a drug or procedure)
- Time in hospital
- In-person visits at study sites — visit count not specified by the sponsor
- Drug or intervention
- Symprove Probiotic (supplement)
- How long the study runs
- Study runs about 11 months (dates as stated)
- About the drug or intervention
- Symprove Probiotic — supplement: Symprove is a water-based, multi-strain probiotic food supplement containing live bacteria (Lactobacillus and Bifidobacterium strains).
- Patient visit burden
- Not specified by the sponsor
- Type of study
- Testing a treatment
- Ages
- 18 Years to 65 Years
- Who
- All
- Number of participants
- 24
- Started
- 2026-01-29
- Last checked
- 2026-03
Plain English Summary
What is this study?
- • Testing a new treatment for coeliac disease
- • NA - 24 participants
- • Coeliac Disease (CD) is a lifelong autoimmune condition where eating gluten (a protein found in wheat, barley, and rye) causes damage to the small intestine
Who can take part?
- • Ages 18 Years to 65 Years
- • Diagnosed with coeliac disease
Where?
- • Sheffield - Sheffield Teaching Hospitals NHS Foundation Trust
This is a simplified summary. Always discuss with your doctor before making any decisions.
About This Trial
Coeliac Disease (CD) is a lifelong autoimmune condition where eating gluten (a protein found in wheat, barley, and rye) causes damage to the small intestine. It affects around 1 in 100 people. Most individuals feel better and their gut heals after switching to a strict gluten-free diet. However, up to 1 in 5 people with coeliac disease continue to experience unpleasant gut symptoms-such as bloating, pain, and diarrhoea-despite following the diet and having a healed intestine. These ongoing symptoms can be very distressing and impact daily life. This study investigates whether a food supplement called Symprove, a probiotic drink containing live good bacteria, can help relieve these ongoing symptoms. Scientists believe that in some people with coeliac disease, the community of bacteria in the gut (called the microbiota) becomes unbalanced, even after going gluten-free. This imbalance (known as dysbiosis) may lead to inflammation, irritation, and symptoms similar to irritable bowel syndrome (IBS). The aim of this study is to test whether Symprove can help correct this imbalance and reduce symptoms. Participants will take Symprove daily and their symptoms, quality of life, and gut bacteria (measured from stool samples) will be monitored over time. The study hopes to answer three key questions: Can Symprove reduce gut symptoms in people with coeliac disease who are in remission? Does it work by restoring a healthy balance of gut bacteria? Are people with more severe imbalance (dysbiosis) more likely to have symptoms? If successful, this research could offer a safe, non-drug option to improve life for coeliac patients who continue to suffer symptoms despite avoiding gluten. It could also help suggest that gut bacteria play a role in ongoing symptoms and are a target for future treatment.
How this trial compares with your answers
Answer 2 more questions to improve match
What we know so far
Still need:
- • Tell us your age for better matching
- • Tell us your sex for better matching
Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.
Eligibility at a Glance
Key info
- Age: 18 Years - 65 Years
- Who can join: All genders
What the study is looking for
- ✓Adults aged 18-65 years with biopsy-confirmed coeliac disease (CD)
- ✓Normal duodenal biopsy (Marsh 0 or Marsh I) within the last 12 months, confirming histological remission
- ✓Adherence to a strict gluten-free diet (GFD) for at least 6 months
- ✓Persistent gastrointestinal (GI) symptoms for at least 6 months despite adherence to GFD and histological remission
- ✓Ability to provide written agreement to take part
Who cannot take part
- ✗Active gluten ingestion or non-adherence to a gluten-free diet
- ✗Use of antibiotics within the past 3 months
- ✗Use of probiotics within the past 3 months
- ✗Known other health conditions affecting gastrointestinal function (e.g., Crohn's disease, ulcerative colitis, irritable bowel...
- ✗Pregnancy or lactation
See the full criteria
Where Is This Study? (1 UK site)
Sheffield Teaching Hospitals NHS Foundation Trust
Sheffield S57AU, United Kingdom
How to Get in Touch
David S Sanders, MBChB, MD
Sponsor contactCONTACT
Arkadeep Dhali, MBBS, MPH
Sponsor contactCONTACT